



Editorial: 5-HT_{2A/2B/2C} Receptors, Memory, and Neuropsychiatric Disorders

Antonella Gasbarri¹, Bettina Bert² and Alfredo Meneses^{3*}

¹ Department of Applied Clinical and Biotechnologic Sciences, University of L'Aquila, L'Aquila, Italy, ² Department of Veterinary Medicine, Institute of Pharmacology and Toxicology, Freie Universität Berlin, Berlin, Germany, ³ Departamento de Farmacobiología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico

Keywords: 5-HT_{2A} receptor, 5-HT_{2B} receptor, 5-HT_{2C} receptors, memory disorders

The Editorial on the Research Topic

5-HT_{2A/2B/2C} Receptors, Memory, and Neuropsychiatric Disorders

It is very well known that memory formation and forgetting represent important cognitive functions modulated by several neurotransmitters, including serotonin (5-hydroxytryptamine, 5-HT) (e.g., Fioravanti and Di Cesare, 1992; Wagner and Davachi, 2001; Wixted, 2004; Mansuy, 2005; Hardt et al., 2013; Hupbach; Callaghan et al., 2014; Li et al., 2015; Meneses), and memory dysfunction is present in several neuropsychiatric disorders (Meyer-Lindenberg et al., 2012; Millan et al., 2012, 2014). How does the brain become dysfunctional? Such a question has intrigued neuroscientists for many years. Over recent decades, neuroscience research has shed light on this complex issue and growing evidence is providing important insights. For instance, several lines of evidence demonstrate that dysfunctions in memory processes occur in several neuropsychiatric disorders, including Alzheimer's disease (AD), characterized by memory deficits and dementia; however, dysfunctional memory is observed in other age-related neurodegenerative disorders, such as schizophrenia, post-traumatic stress disorder, stroke, etc. (Millan et al., 2014; Hashimoto, 2015). So far, no effective treatment for dysfunctional memory exists (e.g., Millan et al., 2012, 2014; Sun et al., 2015); this area is hampered by the absence of neural markers associated to memory. Hence, progress in the fields relating to memory, amnesia, forgetting (e.g., Tellez et al., 2012) and AD (e.g., McConathy and Sheline, 2015; Muenchhoff et al., 2015; Scarr et al., 2015) as well as mild cognitive impairment (Eshkoor et al., 2015) would be facilitated considerably by identification of suitable neural markers. Serotonin is involved in several physiological and pathophysiological processes in mammals and in the treatment of psychiatric disorders (Meneses). It is very well known that 5-HT receptor heterogeneity allows for greater advances, and 5-HT_{2A/2B/2C} receptors are emerging as important tools for preclinical and clinical investigation. This special issue provides a deep overview of important advances on cerebral modifications associated with neuropsychiatric alterations, including dysfunctional memory. In particular, some papers analyse the role of serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia (Sumiyoshi et al.), while others are focused on the missing link of the central serotonin-2A 5-HT_{2A} receptor dysfunction in depression and epilepsy (Guiard and Di Giovanni) and on the activity-regulated cytoskeleton-associated protein's putative role in regulating dendritic plasticity, cognitive processes, and mood in animal models of depression is presented (Li et al.). Moreover, a critical evaluation of serotonin mediation of early memory formation via 5-HT_{2B} receptor-induced glycogenolysis in the day-old chick is provided (Gibbs and Hertz). An important subject is the neuronal localization of the 5-HT₂ receptor family in the amygdaloid complex and emotion memories (Bombardi). Modeling dysfunctional memory, mitochondrial energy metabolism in different regions of the brain and potential treatments is illustrated (Singh and Kumar). In short,

OPEN ACCESS

Edited and reviewed by:

Nicholas Barnes,
University of Birmingham, UK

*Correspondence:

Alfredo Meneses
ameneses@msn.com

Specialty section:

This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Pharmacology

Received: 24 December 2015

Accepted: 12 January 2016

Published: 01 February 2016

Citation:

Gasbarri A, Bert B and Meneses A
(2016) Editorial: 5-HT_{2A/2B/2C}
Receptors, Memory, and
Neuropsychiatric Disorders.
Front. Pharmacol. 7:9.
doi: 10.3389/fphar.2016.00009

the translational feature of this special issue may expand our knowledge on brain dysfunctions and inspire further investigation, thus leading to a better management of psychiatric diseases.

REFERENCES

- Callaghan, B. L., Li, S., and Richardson, R. (2014). The elusive engram: what can infantile amnesia tell us about memory? *Trends Neurosci.* 37, 47–53. doi: 10.1016/j.tins.2013.10.007
- Eshkoor, S. A., Hamid, T. A., Mun, C. Y., and Ng, C. K. (2015). Document mild cognitive impairment and its management in older people. *Clin. Interv. Aging* 10, 687–693. doi: 10.2147/CIA.S73922
- Fioravanti, M., and Di Cesare, F. (1992). Forgetting curves in long-term memory: evidence for a multistage model of retention. *Brain Cogn.* 18, 116–124. doi: 10.1016/0278-2626(92)90073-U
- Hardt, O., Nader, K., and Nadel, L. (2013). Decay happens: the role of active forgetting in memory. *Trends Cogn. Sci.* 17, 111–120. doi: 10.1016/j.tics.2013.01.001
- Hashimoto, K. (2015). Tropisetron and its targets in Alzheimer's disease. *Expert Opin. Ther. Targets* 19, 1–5. doi: 10.1517/14728222.2014.983901
- Li, L. B., Zhang, L., Sun, Y. N., Han, L. N., Wu, Z. H., Zhang, Q. J., et al. (2015). Activation of serotonin_{2A} receptors in the medial septum-diagonal band of Broca complex enhanced working memory in the hemiparkinsonian rats. *Neuropharmacology* 91, 23–33. doi: 10.1016/j.neuropharm.2014.11.025
- Mansuy, I. M. (2005). Forgetting: theories and potential mechanisms. *Med. Sci.* 21, 83–88. doi: 10.1051/medsci/200521183
- McConathy, J., and Sheline, Y. I. (2015). Imaging biomarkers associated with cognitive decline: a review. *Biol. Psychiatry* 77, 685–692. doi: 10.1016/j.biopsych.2014.08.024
- Meyer-Lindenberg, A., Murphy, D., Rolls, E., Saletu, B., Spedding, M., Sweeney, J., et al. (2012). Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. *Nat. Rev. Drug Discov.* 11, 141–168. doi: 10.1038/nrd3628
- Millan, M. J., Agid, Y., Brune, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., et al. (2012). Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. *Nat. Rev. Drug Discov.* 11, 141–168. doi: 10.1038/nrd3628
- Millan, M. J., Agid, Y., Brune, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., et al. (2014). The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's biomarkers standardization initiative. *Alzheimers Dement.* 10, 808–817. doi: 10.1016/j.jalz.2014.03.003
- Muenchhoff, J., Poljak, A., Song, F., Raftery, M., Brodaty, H., Duncan, M., et al. (2015). Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts. *J. Alzheimers Dis.* 43, 1355–1373. doi: 10.3233/JAD-141266
- Scarr, E., Millan, M. J., Bahn, S., Bertolino, A., Turck, C. W., Kapur, S., et al. (2015). Biomarkers for psychiatry: the journey from fantasy to fact, a report of the 2013 CINP Think Tank. *Int. J. Neuropsychopharmacol.* 18:pyv042. doi: 10.1093/ijnp/pyv042
- Sun, M. K., Nelson, T. J., and Alkon, D. L. (2015). Towards universal therapeutics for memory disorders. *Trends Pharmacol. Sci.* 36, 384–394. doi: 10.1016/j.tips.2015.04.004
- Tellez, R., Gómez-Viquez, L., Liy-Salmeron, G., and Meneses, A. (2012). GABA, glutamate, dopamine and serotonin transporters expression on forgetting. *Neurobiol. Learn. Mem.* 98, 66–77. doi: 10.1016/j.nlm.2012.05.001
- Wagner, A., and Davachi, L. (2001). Cognitive neuroscience: forgetting of things past. *Curr. Biol.* 11, R964–R967. doi: 10.1016/S0960-9822(01)00575-9
- Wixted, J. T. (2004). The psychology and neuroscience of forgetting. *Annu. Rev. Psychol.* 55, 235–269. doi: 10.1146/annurev.psych.55.090902.141555

AUTHOR CONTRIBUTIONS

AG wrote the editorial. AM revised and corrected the manuscript. BB worked as referee.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Gasbarri, Bert and Meneses. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.